Table 2. Characteristics of studies not included in the individual participant data meta-analysis.

Study Number and Country/Region	Short Study Name	Primary Publications [Reference]	Reason Not Included in IPD Meta-Analysis	Study Design	Number of Women with HIV/Total Number of Women	Number of Women with HIV in Contraceptive Groups	Comparison Group a	Study Results: Adjusted Effect Measure (95% CI) unless Otherwise Specified b
Studies that did not meet inclusion criteria (n = 8)
19. Rwanda	Not known	Bulterys et al., AIDS 1994 [55]	Did not meet inclusion criteria: follow-up visits >6 mo apart	Cohort	31/1,524	12	No contraception	HC use: OR 1.9 (0.8–4.6)
20. Thailand	Not known	Ungchusak et al., JAIDS 1996 [51]	Not sub-Saharan Africa	Cohort	15/365	NR	No contraception	COC: IRR 0.22 (0.03–1.9); injectable HC: IRR 3.8 (1.0–14.4)
21. Tanzania	Not known	Kapiga et al., AIDS1998 [53]	Did not meet inclusion criteria: follow-up visits >6 mo apart	Cohort	75/2,471	7 (COC); 2 (injectable HC)	No COC use; no injectable use	COC: HR 1.0 (0.5–2.3); injectable HC: HR 0.3 (0.07–1.3)
22. Thailand	Not known	Kilmarx et al., AIDS 1998 [56]	Not sub-Saharan Africa	Cohort	30/340	20 (COC); 5 (DMPA)	No COC use; no DMPA use	COC: RR 1.8 (0.8–4.0); DMPA: unadjusted RR 1.5 (0.6–4.0)
23. Uganda	Rakai Study	Kiddugavu et al., AIDS 2003 [52]	Did not meet inclusion criteria: follow-up visits >6 mo apart	Cohort	202/5,117	12 (COC); 16 (injectable HC)	No contraception, no condoms	COC: IRR 1.1 (0.5–2.6); injectable HC: IRR 0.8 (0.4–1.7)
24. Benin, Ghana, Nigeria, South Africa, Uganda, India	SAVVY/CS Trials	Feldblum et al., Sex Transm Dis 2010 [50]	Did not meet inclusion criteria: no longitudinal data on injectable contraception	RCT	114/7,364	13 (COC); 15 (injectable HC)	No contraception or emergency contraception only	COC: unadjusted RR 1.8 (0.8–4.1); injectable HC: unadjusted RR 2.5 (1.1–5.6)
25. South Africa	CAPRISA 050/051	Abdool Karim et al., Int J Epidemiol 2011 [46]	Did not meet inclusion criteria: longitudinal data on injectable contraception >6 mo apart	RCT	39/594	NA	NA	No published HC—HIV results
26. South Africa, Zambia, Zimbabwe	HPTN 039	Reid et al., JAIDS 2010 [54]	Did not meet inclusion criteria: >5% missing data for exposure	RCT	72/1,358	NR	No contraception, no condoms	COC: HR 0.9 (0.5–1.8); injectable HC: HR 0.9 (0.5–1.9)
Studies not included because agreement was not obtained from investigators (n = 3)
27. South Africa, west Africa, Southeast Asia	COL 1492	Van Damme et al., Lancet 2002 [45]	No agreement/dataset	RCT	99/552	NA	NA	No published HC—HIV results
28. Malawi, South Africa, Zambia, Zimbabwe, US	HPTN 035	Abdool Karim et al., AIDS 2011 [58];; Chirenje et al., Int’l Microbicides Conf. 2012 [61]	No agreement/dataset	RCT	192/2,887	NR	No HC	COC: HR 0.6 (0.3–1.2); injectable HC: HR 1.4 (0.9–2.0)
29. Kenya, Uganda	Partners Prep	Baeten et al., N Engl J Med 2012 [47]	No agreement/dataset	RCT	28/1,584	NA	NA	No published HC—HIV results
Studies with results published after September 2012 (n = 2)
30. Uganda	Rakai Study	Lutalo et al., AIDS 2013 [60]	Does not meet inclusion criteria: follow-up visits >6 mo apart; published after meta-analysis dataset closed	Cohort	30/190	3 (COC); 7 (DMPA)	No contraception, no condoms	COC: IRR 2.7 (0.82–8.6); DMPA: IRR 1.4 (0.6–3.4)
31. South Africa, Uganda, Zimbabwe	VOICE Study	Noguchi et al., CROI 2014 [62]	Published after meta-analysis dataset closed; no non-hormonal-contraceptive comparison	RCT	207/3,141	204	NET-EN use	DMPA: HR 1.4 (1.0–2.0)

^aComparison group, based on information reported by the authors; for study 31 there was no comparison with non-hormonal-contraceptive users, so the comparison group is women using NET-EN.

^b“Injectable” reported if this was the term used by the authors and the specific progestin was not mentioned; all effect sizes rounded to one decimal place.

IRR, incidence rate ratio; NA, not applicable; NR, not reported; OR, odds ratio; RR, risk ratio.